{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:05:25Z","timestamp":1791439525300,"version":"4.3.3"},"reference-count":47,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T00:00:00Z","timestamp":1537920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T00:00:00Z","timestamp":1537920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"published-print":{"date-parts":[[2018,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The role of hyaluronic acid plus hypertonic saline (HA+HS) as a mucoactive treatment in patients with bronchiectasis is still unknown. This study evaluated whether HA+HS solution enhances similar sputum quantity with better safety profile than HS alone in patients with bronchiectasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this double-blind randomized crossover trial, three solutions (7% HS; 0.1% HA +7%HS; and 0.9% isotonic saline, IS) were compared in outpatients with bronchiectasis and chronic sputum expectoration. Participants inhaled each solution across four consecutive sessions. All sessions, except on session 3, also included 30 minutes of airway clearance technique. A 7-day washout period was applied. Sputum weight was collected during the sessions (primary outcome) as well as during a 24-hour follow-up. The Leicester Cough Questionnaire (LCQ) and lung function were measured before\/after each treatment arm. Safety was assessed by the monitoring of adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twenty-eight patients with bronchiectasis (mean age of 64.0 (17.9) and FEV\n                      <jats:sub>1<\/jats:sub>\n                      % 60.9 (24.6) of predicted) were recruited. HS and HA+HS promoted similar expectoration during sessions, both being greater than IS [median difference HS vs. IS 3.7\u2009g (95% CI 0.5\u20136.9); HA+HS vs. IS 3.2\u2009g (95%CI 0.5\u20135.9)]. Sputum expectorated exclusively during the ACT period was similar across all treatment arms [HS vs. IS \u22120.3\u2009g (95% CI \u22121.7 to 0.9); HA+HS vs. IS 0.0\u2009g (95% CI \u22121.3 to 1.4); HS vs. HA+HS 0.0\u2009g (95% CI \u22121.2 to 0.4)]. Sputum collected over the 24-hour follow-up tended to be lower for HS and HA+HS compared with IS [HS vs. IS \u22121.7\u2009g (95% CI \u22124.2 to 0.0); HA+HS vs. IS \u22121.1\u2009g (95%CI \u22123.6 to 0.7)]. No differences in LCQ or lung function were observed. Most severe AEs were reported using HS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>HS and HA+HS were more effective on sputum expectoration than IS in patients with bronchiectasis, reporting HA+HS better safety profile than HS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jamp.2017.1443","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T14:58:57Z","timestamp":1528383537000},"page":"281-289","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":52,"title":["Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial"],"prefix":"10.1177","volume":"31","author":[{"given":"Beatriz","family":"Herrero-Cortina","sequence":"first","affiliation":[{"name":"Universidad San Jorge","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Alcaraz","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Vilar\u00f3","sequence":"additional","affiliation":[{"name":"Universitat Ramon Llull","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Torres","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Polverino","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona"},{"name":"Institut de Recerca Valld'Hebron (VHIR)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,9,26]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-206956"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00629-2017"},{"issue":"2","key":"e_1_3_4_4_2","first-page":"S186","article-title":"Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic Fibrosis","volume":"13","author":"Bennett WD","year":"2016","unstructured":"Bennett WD, , Henderson AG, , and Donaldson SH: Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic Fibrosis. Ann Am Thorac Soc. 2016; 13 Suppl 2:S186\u2013S190.","journal-title":"Ann Am Thorac Soc"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2004.05.006"},{"key":"e_1_3_4_6_2","first-page":"CD002996","article-title":"Inhaled hyperosmolar agents for bronchiectasis","volume":"5","author":"Hart A","year":"2014","unstructured":"Hart A, , Sugumar K, , Milan SJ, , Fowler SJ, , and Crossingham I: Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev. 2014; 5:CD002996.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2016.1278019"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043891"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2012.1034"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043900"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.09540327"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-010-0076-8"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2015.1256"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200205-449PP"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2016.1318"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201005-0756OC"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00055509"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.07.012"},{"key":"e_1_3_4_19_2","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2018. Available from www.ginasthma.org accessed March15 2018."},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1836-9553(12)70070-X"},{"key":"e_1_3_4_21_2","first-page":"50","article-title":"Application of positive expiratory pressure *PEP* in cystic fibrosis patient inhalations","volume":"19","author":"Orlik T","year":"2015","unstructured":"Orlik T, and Sands D: Application of positive expiratory pressure *PEP* in cystic fibrosis patient inhalations. Dev Period Med. 2015; 19:50\u201359.","journal-title":"Dev Period Med"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.physio.2015.07.005"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009720"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.physio.2006.07.005"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/cpf.12085"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01926-2017"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/1479972316632005"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-79842-2_16"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034805"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.136119"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(10)60241-X"},{"key":"e_1_3_4_32_2","volume-title":"Statistics with Confidence","author":"Campbell MJ","year":"2000","unstructured":"Campbell MJ, and Gardner M: Medians and their differences. In: Statistics with Confidence, Second edition. Altman D, , Machin D, , Bryant T, , and Gardner M (eds). BMJ books, Bristol, UK. 2000."},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-10-200411160-00009"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.03.017"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/0962280214521349"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0296"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-009-9198-7"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-61452-6_18"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.12.016"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S142156"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/2213-0802-2-6"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.04087"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-10-27"},{"key":"e_1_3_4_44_2","first-page":"CD008816","article-title":"Timing of hypertonic saline inhalation for cystic fibrosis","volume":"12","author":"Elkins M","year":"2016","unstructured":"Elkins M, and Dentice R: Timing of hypertonic saline inhalation for cystic fibrosis. Cochrane Database Syst Rev. 2016; 12:CD008816.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2016-000168"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-017-0038-x"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.07521348"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.12.021"}],"container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jamp.2017.1443","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2017.1443","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2017.1443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:10:19Z","timestamp":1777644619000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jamp.2017.1443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,26]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10,1]]}},"alternative-id":["10.1089\/jamp.2017.1443"],"URL":"https:\/\/doi.org\/10.1089\/jamp.2017.1443","relation":{},"ISSN":["1941-2711","1941-2703"],"issn-type":[{"value":"1941-2711","type":"print"},{"value":"1941-2703","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,26]]}}}